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Abstract 
Phospholipase A 2 (PLA 2) activity has been suggested to mediate some of the tumor necrosis factor (TNF) induced cellular esponses 
including cytotoxicity. We evaluated the induction of both the 85-kDa cytosolic phospholipase A 2 (cPLA 2) and non-pancreatic group II 
PLA 2 gene expression by TNF-ot in a human bronchial epithelial cell line (BEAS 2B cell). TNF-ct (20 ng/ml) induced a significantly 
increased release of prelabeled [3H]arachidonic acid (AA) following 4-24 h incubation. Calcium ionophore A23187 (10 -5 M) further 
increased the [3H]AA release from the TNF-zt-treated cells. In vitro activity assay revealed that TNF-ot increased the dithiothreitol 
(DTT)-reSistant PLA 2 activity which was blocked by the cPLA 2 inhibitor AACOCF 3. Treatment with TNF-ot for 4-24 h increased the 
cPLA 2 protein and mRNA levels which were blocked by the broad inhibitor of protein kinases taurosporine, the protein kinase C (PKC) 
inhibitor calphostin C, and to a lesser extent he calcium/calmodulin-dependent protein kinase inhibitor W-7. Reverse transcription and 
polymerase chain reaction amplification of the group II PLA 2 mRNA showed that it is expressed in human lung but not in the bronchial 
epithelial cell line. TNF-ct failed to induce the expression of group II PLA 2 in the BEAS 2B cells. These results demonstrate hat the 
cPLA 2 gene expression is up-regulated by TNF-ct and this effect may contribute to the TNF-cc stimulated AA release in airway 
epithelial cells. 
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1. Introduction 
Tumor necrosis factor (TNF), a potent cytokine pro- 
duced primarily by activated macrophages and monocytes, 
has a wide range of activities in various cell types [1-3]. It 
elicits a large number of biological effects, including hem- 
orrhagic necrosis of transplanted tumors and cytotoxicity. 
It may have a role in endotoxic shock and in inflammatory, 
immunoregulatory, proliferative, and antiviral responses. 
TNF induces the release of AA and production of potent 
lipid inflammatory mediators, such as prostaglandins (PGs), 
leukotrienes (LTs), and platelet-activating factor (PAF) in 
many types of cells [4-10], suggesting that TNF-cx may 
have a direct effect on phospholipase A 2 (PLA 2) activa- 
tion. As the PLA 2 initiated lipid mediators have been 
implicated in many physiological and pathophysiological 
effects in a variety of cells [11-14], the activation of PLA 2 
may be involved in the multifunctional biological actions 
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of TNF. A substantial body of evidence suggests that 
TNF- cx induced cytotoxicity is mediated at least in part by 
PLA 2 activity. This conclusion is based on the following 
observations: (a) PLA 2 activity exists in TNF-sensitive 
cells, but not in TNF-resistant cells [9,15,16]; (b) PLA 2 
inhibitors protect cells from TNF induced cytotoxic action 
[7,8,10,15,16]; and (c) induction of AA release, such as by 
Li ÷ ions, enhances the TNF-initiated cytotoxicity [10]. 
Some TNF-resistant cells can be sensitized with inhibitors 
of transcription (actinomycin D) or translation (cyclo- 
heximide) which block the synthesis of some putative 
cellular PLA2-inhibitory proteins and thus increase PLA 2 
activity [5]. In other cells (e.g., endothelial cells), TNF 
increases PLA2 activity by stimulating the synthesis of a 
PLA 2 activating protein (PLAP) and co-treatment with 
actinomycin D and cycloheximide blocks the synthesis of 
PLAP and thus inhibits PLA 2 activity [4]. Taken together, 
evidence obtained from various cells suggests that TNF 
may regulate PLA 2 activity by control PLA 2 enzyme 
protein or other cellular proteins which regulate PLA 2 
activity. 
176 T. Wu et al. / Biochimica et Biophysica Acta 1310 (1996) 175-184 
PLA 2 s are distinct families of enzymes that catalyze the 
hydrolysis of the sn-2-ester bond of phospholipids, result- 
ing in the production of free fatty acids and lysophospho- 
lipids [11-14]. These products may serve as intracellular 
second messengers or can be further metabolized to the 
potent inflammatory mediators, such as PGs, LTs, 
hydroxyeicosatetraenoic acids (HETEs), or PAF [11- 
14,17-19]. The major mammalian PLA2s include the low 
molecular weight (10-14 kDa) secreted forms (sPLA 2) 
[20-23] and the structurally unrelated high molecular 
weight (85 kDa) cytosolic PLA 2 (cPLA 2) [24-27]. While 
the role of other forms of PLA 2 s in AA metabolism and 
eicosanoid production remains to be defined, recent studies 
have demonstrated that the cPLA 2 plays an important role 
in AA metabolism [24-28]. The cPLA 2 preferentially 
hydrolyzes phospholipids containing arachidonic acid (AA) 
esterified in the sn-2 position. The cPLA 2 has two func- 
tionally distinct domains, the Ca2+-independent catalytic 
domain and the regulatory Ca2+-dependent lipid binding 
domain (CaLB) [25] which mediates the translocation of 
cPLA 2 from cytosol to cell membranes in the presence of 
Ca 2+. The activity of cPLA 2 is increased in the presence 
of Ca 2+ or after enzyme phosphorylation [29]. Platelet-de- 
rived growth factor (PDGF), epidermal growth factor 
(EGF), ATP, thrombin and phorbol 12-tetradecanoate 13- 
acetate (TPA) cause phosphorylation f the serine or threo- 
nine residues of the cPLA 2 and result in enhanced enzyme 
activity [29]. Phosphorylation at serine-505 by mitogen- 
activated protein (MAP) kinase causes an increase in 
cPLA 2 activity [30,31]. In addition to serine/threonine 
phosphorylation, tyrosine phosphorylation has also been 
suggested in the transforming rowth factor-cx (TGF-ct) 
induced activation of cPLA 2 [32]. While the activity of the 
cPLA 2 enzyme can be regulated by the above agents, it 
has been recently demonstrated that the cPLA 2 enzyme 
protein synthesis can also be regulated by several cy- 
tokines including interleukin-1 ot (IL-1 or) in fibroblasts 
[33], macrophage colony-stimulating factor (M-CSF) in 
monocytes [34] and interferon-y in the airway epithelial 
cells [35]. Recently, it has been demonstrated that the 
cPLA 2 is crucial in TNF at-mediated cytotoxicity [36]. In 
a separate study, Hoeck et al. reported that cPLA 2 medi- 
ated the TNF-cx-induced biphasic release of prelabeled 
AA in Hela cells [37]. Thus the cPLA 2 may play an 
important role in mediating the diverse functions of TNF. 
Mammalian low molecular weight PLA2s mainly in- 
clude two types. The group I PLA 2 comprises the pancre- 
atic type of PLA 2 and is characterized by the presence of 
Cysll .  Several non-pancreatic tissues contain group II 
PLA 2, which is characterized by the lack of Cysl 1. The 
group II PLA 2 (but not group I) has been suggested to be 
involved in the pathogenesis of inflammatory reactions 
[11-14]. It is found at inflammatory sites such as peri- 
toneal exudates and rheumatoid arthritis synovial fluid or 
in the serum of patients with septic shock [11-14]. It is 
synthesized and secreted from many cell types and is 
believed to play a role in the initiation and propagation of 
inflammatory processes. Its expression is up-regulated by 
proinflammatory c tokines including TNF, IL-1 and IL-6 
[11-14]. Recently, the group II PLA 2 has been found to 
mediate prostaglandin production in P338D 1 macrophage- 
like cells [38]. This finding indicates that the group II 
PLA 2 may also play a role in eicosanoid production. As 
previous tudies have demonstrated that TNF increases the 
group II PLA 2 mRNA and enzyme protein level in renal 
mesangial cells and hepatoma cells [39,40], it is possible 
that the group II PLA 2 induced by TNF treatment may at 
least partially contribute to the TNF induced AA release in 
these cell types. 
The respiratory epithelia of several mammals ecrete 
large amounts of uteroglobin/Clara cell 10 kDa protein, a 
family of proteins that inhibit low molecular weight PLA 2 s 
[14]. Freshly isolated or cultured airway epithelial cells are 
able to generate and release AA metabolites and PAF in 
response to various stimuli. The release of these mediators 
may be important in the pathogenesis of disorders charac- 
terized by airway inflammation, such as asthma. Thus, the 
airway epithelium ay play an active role in initiating and 
modulating airway inflammation [41]. However, it remains 
difficult to discriminate between contributions of different 
types of PLA2s in the liberation of AA and subsequent 
formation of eicosanoids in various cell types including the 
airway epithelial cells. The present study has been de- 
signed to study the effect of TNF-ct on both the cPLA2 
and non-pancreatic group II PLA 2 gene expression in a 
bronchial epithelial cell line (BEAS 2B cells). We found 
that TNF-ct induced a significantly increased release of 
[3H]AA from prelabeled cells. In vitro activity assay re- 
vealed that TNF-~ increased the dithiothreitol (DTT)-re- 
sistant PLA 2 activity which was blocked by the cPLA 2 
inhibitor AACOCF 3. TNF-at treatment increases the ex- 
pression of cPLA 2 protein and mRNA. While the group II 
PLA 2 is expressed in human lung, it does not exist in the 
BEAS 2B cells and TNF- ct failed to induce its expression 
in these cells. These results demonstrate hat the cPLA 2 
gene expression is up-regulated by TNF-~ and this effect 
contributes to the TNF-ot stimulated AA release in the 
airway epithelial cells. 
2. Materials and methods 
2.1. Cell culture 
BEAS-2B cells, a human bronchial epithelial cell line 
transformed by an adenovirus 12-SV40 hybrid virus, was a 
gift from Dr. J.E. Lechner and Dr. C.C. Harris, National 
Cancer Institute, National Institutes of Health, Bethesda, 
MD [42]. The cells were maintained in serum-free, hor- 
monally defined culture media, LHC-8 (Biofluids Inc., 
Rockville, MD) and grown on 175 cm 2 tissue culture 
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flasks (Falcon/Becton Dickinson, Oxnard, CA) which 
were coated with a thin layer of rat tail collagen, Type I 
(Collaborative Research, Bedford, MA). Experiments were 
performed when the cells reached confluence (approx. 30 
million cells/flask). 
2.2. Arachidonic acid release 
The BEAS 2B cells grown on 175 cm 2 culture flasks 
were labeled for 18 h with 1 /xCi/ml [5,6,8,9,11,12,14,15- 
3H]arachidonic acid (214 Ci/mmol, Amersham, Arlington 
Height, IL) in LHC-8 media. Following repeated washing 
with media, 20 ml of fresh media were added to each 
flask. Subsequently, some cultures were exposed to TNF- cx 
(20 ng/ml), while others were maintained as controls. 
Following 4-24 h incubation with TNF-~,  the super- 
natants were harvested. The samples were extracted by 
Sep-Pak C~8 cartridges and chromatographed by reverse- 
phase high pressure liquid chromatography (HPLC) as 
previously described [43-45]. Individual octadecyl-silane 
(ODS) C18 cartridges(Sep-Pak C18; Waters Associates, 
Milford, MA) were prepared with 15 ml of methanol 
followed by 5 ml of 5 mM ethylenediaminetetra-acetic 
acid and 10 ml of water. Samples were loaded onto the 
cartridges, washed with 10 ml of water, and eluted with 4 
ml of methanol. The methanol fraction was collected, 
evaporated to dryness under steady flow nitrogen gas and 
resuspended in 200 /xl of mobile phase A (see below) for 
analysis by HPLC. An Ultrasphere C18 (Beckman Instru- 
ments, Fullerton, CA) column (4.7 mm X 250 mm) with 
5-/xm particle size was used. A gradient program was used 
with mobile phase A: water/acetonitrile/phosphoric acid 
(75:25:0.025), and mobile phase B: methanol/aceto- 
nitrile/trifluoroacetic acid (60:40:0.0016) ata flow rate of 
1.5 ml/min. The arachidonic acid fraction of HPLC elu- 
tion was collected and measured for radioactivity. 
2.3. Assay of PLA 2 activity 
PLA 2 activity was assayed by modification of a previ- 
ously described method [35]. Confluent BEAS 2B cells 
grown on 175 cm z flasks were incubated with TNF-oc. At 
the indicated times, treated and control cells were rinsed 
twice and digested with 0.1% collagenase for 10 min. 
Following washing 3 times with cold Hank's Balanced 
Salt Solution without calcium and magnesium [HBSS(- )], 
the cells were transferred to 0.5 ml of homogenization 
buffer: 50 mM Hepes (pH 8.0), 1 mM EDTA, 1 mM 
EGTA, 50 /xg/ml leupeptin, 1 mM dithiothreitol (DTT), 
0.5 mM phenylmethylsulfonyl fluoride, 10 /~M phospho- 
ramidon, 10/xg/ml soybean trypsin inhibitor, 100/xg/ml 
aprotinin. Cells in homogenization buffer were sonicated 
for 4 X 15 s using a microprobe. The homogenate was 
centrifuged at 1000 X g for 5 min to remove nuclei, 
unbroken cells, and debris. The crude cell lysate was 
assayed for PLA 2 activity with sn-2 [14C]arachidonyl 
phosphatidylcholine as substrate (53.0 mCi/mmol, NEN, 
Boston, MA). Substrates were dried under nitrogen and 
resuspended in dimethyl sulfoxide. Two /zl of substrate 
(final concentration 15 tzM) was pipetted into an Eppen- 
doff microcentrifuge tube. Reactions were initiated by the 
addition of 2.5 /~1 of 116 mM calcium stock (final calcium 
concentration 2.9 mM, 0.9 mM in excess of the combined 
EDTA and EGTA concentrations) and 95.5/zl of the crude 
cell lysate. For reactions with the cPLA 2 inhibitor, 0.4/xl 
of ethanol stock solution containing AACOCF 3 was in- 
cluded in the reaction mixture (final concentration of 
AACOCF 3 is 50 /xM). This amount of ethanol had no 
effect on the assayed PLA 2 activity. The reaction mixture 
was incubated for 15 min at 37°C and terminated by the 
addition of 300/xl of 2:1 chloroform/methanol c ntaining 
1% acetic acid and 1 mg/ml free AA. Release of free fatty 
acid was analyzed using silica gel H thin layer chromatog- 
raphy plates (Analtech, Newark, DE). After vigorous vor- 
texing and a brief centrifugation, 75 tzl of the chloroform 
phase was spotted on the plates, and the plates were 
developed with heptane/isopropryl ether/acetic acid 
(60:40:4). Under this system, free arachidonic acid is well 
resolved from diglycerides and unhydrolyzed phospho- 
lipids. Free AA was then scraped and quantified by scintil- 
lation counting. PLA 2 activity was calculated as picomoles 
of AA released per mg of protein. The samples were 
assayed for protein in triplicate (BCA Protein Assay, 
Pierce, Rockford, IL). 
2.4. Immunoblot of cPLA 2 protein 
Confluent BEAS 2B cells grown on 175 cm 2 flasks 
were incubated with TNF-cx (20 ng/ml). At the indicated 
times, treated and control cells were rinsed twice and 
digested with 0.1% collagenase for 10 min. Following 
washing 3 times with cold HBSS(-) ,  the cells were 
transferred to 0.5 ml of homogenization buffer: 50 mM 
Hepes (pH 8.0), 1 mM EDTA, 1 mM EGTA, 50 /xg/ml 
leupeptin, 1 mM dithiothreitol, 0.5 mM phenylmethyl- 
sulfonyl fluoride, 10 /xM phosphoramidon, 10 /zg/ml 
soybean trypsin inhibitor, 100 /xg/ml aprotinin. Cells in 
homogenization buffer were sonicated for 4 X 15 s using a 
microprobe. The homogenate was centrifuged at 1000 X g 
for 5 min to remove nuclei, unbroken cells, and debris. 
The low speed supernatant was ultracenfrifuged at 100 000 
x g for 1 h to produce a soluble fraction (crude cytosol). 
Ten /~g of crude cytosol protein was subjected to SDS- 
PAGE on 8% polyacrylamide gels using Tris glycine 
buffer. The separated proteins were electrophoretically 
transferred onto a nitrocellulose membrane, which was 
blocked with 5% non-fat milk overnight, hen probed with 
a 1:1000 dilution of rabbit anti-cPLA 2 (provided by the 
Genetics Institute, Boston, MA) and finally detected with a 
1:1000 dilution of horseradish-peroxidase-labeled protein 
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A using the ECL Western Blotting Detection system 
(Amersham, Arlington Height, IL). 
2.5. Nuclease protection assay (RPA) 
Cells were treated with TNF-¢x for 4-24 h with or 
without inhibitors. Inhibitors were added to the culture 10 
min prior to the addition of TNF-cx (20 ng/ml). Lactate 
dehydrogenase was measured in the supernatant to assess 
the possible cytotoxicity of TNF-cx and the inhibitors. 
TNF-cx as well as all the inhibitors did not exhibit any 
cytotoxicity effect at the tested concentrations. Total cellu- 
lar RNA was extracted from 175 cm 2 culture flasks by the 
single step guanidinium thiocyanate-phenol-chloroform ex- 
traction method. The RNA pellet was precipitated with 
isopropanol and washed twice with 70% ethanol and redis- 
solved in diethylpyrocarbonate water. The cPLA 2 (306 
bases long; bases 799-1104) and GAPDH (316 bases long) 
probes were prepared by in vitro transcription using 
[32p]CTP and SP6 or T7 RNA polymerases. A RNase 
protection assay kit (RPA II) (Ambion, Austin, Texas) was 
used for the following procedures. Hybridization was per- 
formed at 45°C for 16 h with 10 (for GAPDH) or 20 (for 
cPLA 2) p,g of total RNA and 10 4 (for GAPDH) or 105 
(for cPLA 2) cpm of the 32p-labeled probe. After hy- 
bridization, 200/zl of RNase digestion buffer containing 1
unit/ml RNase A and 40 units/ml RNase T1 was added 
and the samples were incubated at 37°C for 30 min. After 
completion of digestion, RNases were inactivated and 
nucleic acids were precipitated by adding 300 /xl of RNase 
inactivation/precipitation mixture. RNA:RNA duplexes 
were denatured at 95°C for 5 min and analyzed by 6% 
polyacrylamide/7 M urea gel and autoradiography. The 
assay was found to be linear when a series of dilutions of 
total RNA from TNF- c~ stimulated cells were used (2-, 1-, 
0.5-, and 0.25-fold). 
2.6. Nuclear run-on assay 
Nuclear run-on assays were performed as described 
[35]. Confluent, quiescent cultures of BEAS-2B cells were 
stimulated with TNF-oc (20 ng/ml) for 30 min to 4 h and 
digested with 0.1% collagenase in HBSS( - )  for 10 min. 
Following washing twice with cold HBSS(-) ,  the cell 
pellet was resuspended in 4 ml NP40 lysis buffer (10 mM 
Tris-HC1 [pH 7.4], 10 mM NaC1, 3 mM MgC12, 0.5% 
(v/v)  Nonidet P-40, 50 p,g/ml leupeptin, 1 mM dithio- 
threitol, 0.5 mM phenylmethylsulfonyl fluoride and 100 
~g/ml  aprotinin), incubated for 5 min on ice, and cen- 
trifuged at 500 X g for 5 min. The nuclear pellet was 
washed once with 4 ml NP40 lysis buffer and centrifuged 
at 500 X g. The supernatant was discarded, the nuclei were 
resuspended in 200 p,1 reaction buffer (10 mM Tris-HC1 
[pH 8.0], 5 mM MgC12, 300 mM KC1, 1 mM dithio- 
threitol, 0.5 mM each of ATP, CTP, and GTP and 200 
/zCi of [a-32 P]UTP (3000 Ci/mmol, NEN, Boston, MA) 
and reacted at 30°C for 1 h. RNA was extracted by 
guanidinium thiocynate-phenol-chloroform extraction 
method with the addition of 100 /zg yeast carrier tRNA. 
The samples were resuspended to equal counts/min/ml in
hybridization buffer (2 × 10 7 cpm/ml) containing 50 mM 
Pipes (pH 6.8), 10 mM EDTA, 600 mM NaCI, 0.2% SDS, 
and 100 /zg/ml denatured salmon tests DNA. Hybridiza- 
tion to denatured cytosolic PLA 2 and chloramphenicol 
acetyltransferase (CAT) DNAs slot blotted on nitrocellu- 
lose filters was performed at 65°C for 40 h following 
prehybridization at 80°C for 2 h in hybridization buffer 
containing 1% SDS. After hybridization the filters were 
washed in 2 × SSC, 0.1% SDS for 1 h X 2, air-dried and 
exposed to X-ray film for overnight. For binding to nitro- 
cellulose, the PCR amplified cPLA 2 fragment (306 bases 
long; bases 799-1104) [35] and CAT gene DNA (Phar- 
macia, Piscataway, NJ) were denatured by incubation with 
0.2 N NaOH for 30 min at room temperature. The DNA 
was spotted onto nitrocellulose using the Schleicher and 
Schuell slot blot apparatus. 
2.7. Reverse transcription and polymerase chain reaction 
(RT-PCR) 
Cells were treated with TNF-cx for various time points. 
Total cellular RNA was purified as described above and 
redissolved in 5 /xl diethylpyrocarbonate water. Prior to 
RT-PCR, 5 p,l of RNase free DNase I (10000 U/ml, 
Stratagene, La Jolla, CA) was added and incubated at 37°C 
for 30 rain to digest any possible contaminating DNA. The 
RNase free DNase was heat-inactivated at 95°C for 5 min 
and then cooled to 4°C. Total RNA (5 /zg/reaction) was 
reverse transcribed into cDNA at 42°C for 15 min using 
Moloney murine leukemia virus (MMLV) reverse tran- 
scriptase and oligo d(T)16 primers (GeneA-'np RNA PCR 
Kit, Perkin Elmer Cetus, Norwalk, CT). To detect group II 
non-pancreatic PLA 2 and fl-actin mRNA in the lung 
tissue, 50 ng of human lung poly(A)+ RNA (Clontech 
Laboratories, Palo Alto, CA) was used for reverse tran- 
scription under identical conditions. The reverse transcrip- 
tase was then heat-inactivated at 99°C for 5 rain and the 
cDNA cooled to 4°C. The cDNA was amplified via PCR 
utilizing Thermus aquaticus DNA polymerase. The reac- 
tion was carried out for 45 cycles with 1 /xM of 5' and 3' 
primers in 100 p,l of reaction mixture using a step program 
(94°C, 1 min; 55°C, 1 min; 72°C, 2 min), followed by a 
10-min final extension at 72°C. The products were elec- 
trophoresed on a 1% agarose/3% NuSieve GTG agarose 
gel and stained with ethidium bromide. The group II PLA 2 
primer pair was constructed according to the cDNA se- 
quence [23]. It amplified a 823 bp product and was com- 
posed of the following sequences: 5' primer-CAACTCTG- 
GAGTCCTCTGAGAGAGCC (8-33); 3' Primer- 
GCTAATTGCTTTATTCAGAAGAGAC (830-806). The 
sequence of the primers for cPLA 2 and fl-actin has been 
described previously [35]. The cytosolic PLA 2 primer pair 
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amplified a 306 bp PCR product (799-1104) and the 
/3-actin primer pair amplified a 510 bp product (660-1169). 
The 306 bp PCR product of cytosolic PLA 2 was cloned 
into the pCR II vector (Invitrogen, San Diego, CA) to 
synthesize the radiolabeled probe for the measurement of 
cPLA 2 mRNA by RPA. The identity of the cloned PCR 
fragment was confirmed by DNA sequencing. 
2.8. Materials 
Recombinant human TNF- cc was purchased from R & D 
systems, Minneapolis, MN. Non-radiolabeled nucleotides 
were purchased from Pharmacia, Piscataway, NJ. 
AACOCF 3, staurosporine, calphostin C, genistein, W-7, 
phenylmethylsulfonyl fluoride, ionophore A23187 and non 
radiolabeled AA were purchased from Calbiochem, La 
Jolla, CA. Aprotinin was purchased from ICN Biochemi- 
cals, Cleveland, OH. Phosphoramidon was purchased from 
Peninsula Laboratories, Belmont, CA. Soybean trypsin 
inhibitor was purchased from Biofluids, Rockville, MD. 
Lactate dehydrogenase assay system and all other chemi- 
cals were purchased from Sigma Chemicals, St. Louis, 
MO. 
3. Results 
3.1. The effect of TNF-cx on [3H]AA release 
The effect of TNF on AA release from intact cells was 
measured by prelabeling the cells with [3H]AA. TNF-cz 
(20 ng /ml )  induced a significantly increased release of 
[3H]AA following 4 -24  h incubation (Fig. 1). The maxi- 
mal release was observed at 12 h. These results demon- 
strate that prolonged treatment of the cells with TNF-c~ 
Table 1 
< T1 > The effect of TNF-ot on PLA 2 activity 
No AACOCF 3 50/xM AACOCF 3 
Control 25.1 + 3.2 7.9+0.5 
TNF-a 4 h 60.0+5.8 ** 9.5+0.6 
TNF-a 12 h 62.4+3.8 ** 8.9+0.5 
TNF-a 24 h 59.0+3.6 ** 9.4___0.3 
Cells were treated with TNF-a for 4-24 h. The PLA z activity was 
assayed as described in Section 2. The results (pmol/mg protein) were 
expressed as mean + S.E.M. for n = 4 individual experiments. * * P < 
0.01 (compared with control, Bonferroni-adjusted Student's t-test </TI  
> 
increases the release of prelabeled [3H]AA in the BEAS 
2B cells. 
3.2. The effect of TNF-ot on PLA 2 activi O" 
As TNF-ot increased intact cell PLA 2 activity, which 
is reflected by the increased [3H]AA release, we then 
measured the in vitro PLA 2 activity under the conditions 
optimal for the cPLA 2. The measured activity was depen- 
dent on added Ca 2+ and resistant to DTT. The cells were 
treated with TNF- ot for 4 -24 h and lysed in Ca2+-free 50 
mM Hepes buffer (pH 8.0) containing calcium chelators, 
DTT and other proteinase inhibitors. TNF-~ significantly 
increased PLA 2 activity after 4 -24 h incubation (Table 1). 
In both the control and TNF- cc -treated cells, the measured 
activity was significantly decreased in the presence of 
AACOCF 3, a specific inhibitor of cPLA 2. Moreover, the 
PLA 2 activity induced by TNF- at was completely blocked 
by AACOCF 3. These results suggest hat the activity of 
cPLA 2 is significantly increased following treatment with 
TNF- cc for 4 -24 h. 
15000 
~" 10000 o. 
iI1 
_1 
iiJ 
[ ]  CONTROL 
[ ]  TNF~ 
5000 
0 ~ ~  
4h 12h 24h 
Fig. 1. The release of [3H]AA by BEAS 2B cells. The cells were grown on 175 cm 2 culture flasks in LHC-8 media nd labeled with [3H]AA (1 ~Ci/ml) 
for 18 h. Following repeated washing with media, 20 ml of fresh media were added to each flask. Subsequently, some cultures were exposed to TNF-oc 
(20 ng/ml), while others were maintained as controls. Following 4, 12 or 24 h incubations with TNF-ct, the supernatants were harvested. The samples 
were chromatographed by HPLC and AA fractions collected and measured for radioactivity. The results were expressed asthe amount of [3H]AA released 
(dpm) per flask. The values represent mean + S.E.M. of 3-5 separate experiments. Student paired t-test was used for analysis. 
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Fig. 2. The effect of TNF-a on the amount of cPLA 2 protein. The cells 
were treated with TNF- ct for 4-24 h and the crude cytosol was isolated 
for Western blot. Ten /xg of crude cytosol protein was subjected to 
SDS-PAGE. The blot was probed with a 1:1000 dilution of rabbit 
anti-cPLA 2 and detected with a 1:1000 dilution of horseradish-per- 
oxidase-labeled protein A using the ECL Western blotting detection 
system. The cPLA 2 protein (110 kDa) was shown from left as following: 
control cells; cells treated with TNF-cc (20 ng/ml)  for 4-24 h. The 
result shown is the representative of 3 seperate xperiments. 
3.3. The effect of TNF-cx on the amount o f  cPLA 2 protein 
cPLA 2 -  
Fig. 3. Effects of protein kinase inhibitors on cPLA 2 protein amount. 
Confluent BEAS 2B cells were treated with TNF-cc for 4 h with or 
without inhibitors. Inhibitors were added to the culture 10 min before the 
addition of TNF-at (20 ng/ml).  The effects of various protein kinase 
inhibitors were displayed from the right as following: control cells; cells 
treated with TNF-ct; and cells treated with TNF-ct in the presence of 
staurosporine (2x10  -7 M), calphostin C (10 -7 M), genistein (0.1 
mg/ml),  and W-7 (30 /zM). Ten /zg of crude cytosol protein was 
subjected to SDS-PAGE. Western blot was performed as described 
above. The result shown is the representative of 3 seperate xperiments. 
As prolonged treatment of the cells with TNF-cx 
induced an increased release of [3H]AA as well as an 
increased PLA 2 activity assayed in the presence of DTT, 
we then assessed whether the increased PLA 2 activity was 
due to increased cPLA 2 synthesis. Immunoblot of the 
crude cytosol fractions prepared from the control and 
TNF-cx treated cells was performed using a specific anti- 
body to cPLA 2. The cPLA 2 protein (110 kDa) was in- 
creased following treatment with TNF- ct for 4, 8, 12, and 
24 h (Fig. 2). In addition, the possible effect of various 
protein kinase inhibitors on the TNF-ot induced cPLA 2 
protein synthesis was studied. The TNF-c( induced in- 
crease in cPLA 2 protein was inhibited by the broad in- 
hibitor of protein kinases staurosporine and the protein 
kinase C (PKC) inhibitor calphostin C, and to a lesser 
extent by the calcium/calmodulin-dependent protein ki- 
nase inhibitor W-7 (Fig. 3). The tyrosine kinase inhibitor 
genistein had no effect. These results suggest that the 
TNF- at induced cPLA 2 protein increase may require PKC 
as well as calcium/calmodulin-dependent protein kinases. 
3.4. The effect of calcium ionophore A23187 on [3H]AA 
release from TNF- ot -treated cells 
The cPLA 2 enzyme protein undergoes further post- 
translational modification such as enzyme phosphorylation 
and calcium modulation. It has been well established that 
the calcium binding domain (CaLB) of cPLA 2 binds to 
calcium and mediates the enzyme translocation from cyto- 
plasm to membrane phospholipid substrate [25]. As TNF- ot 
induces the synthesis of cPLA 2 protein, we expected that 
12,000- -  
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6,000 - -  
O 
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Fig. 4. The HPLC chromatogram of ionophore A23187 induced [3 H]AA release from control and TNF-ot -treated cells. The cells were prelabeled with 
[3H]AA and followed by TNF-ot treatment for 12 h. After washing the cells twice with I-IBSS, the cells were incubated with or without 10 -5 M 
ionophore A23187 for 15 min in HBSS containing 1.3 mM Ca 2 +. The samples were extracted by Sep-Pak C is cartridges and chromatographed by HPLC. 
AA is eluted at fraction 59. The chromatogram is a representative of 5 separate xperiments. 
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the induced cPLA 2 enzyme protein would provide an 
enzyme source to be further activated by a second stimulus 
such as an increase in the intracellular calcium concentra- 
tion. Therefore, the TNF-ot-treated cells would exhibit 
further increased cPLA 2 activity and increased AA release 
in response to the calcium ionophore A23187. To this end, 
the cells were initially labeled with [3H]AA for 18 h and 
followed by treatment with TNF-ot (20 ng/ml, 12 h). 
After washing twice with media, the cells were subse- 
quently incubated with or without 10 -5 M ionophore 
A23187 for 15 min in HBSS containing 1.3 mM Ca 2+. 
While TNF-~-induced [3H]AA release remained in- 
creased in this 15-min incubation period, the cells treated 
with TNF-oc as well as the calcium ionophore A23187 
exhibited ramatically increased [3H]AA release compared 
with cells treated with TNF-ot alone or the ionophore 
A23187 alone (Fig. 4). This result suggests that the TNF- 
cx-induced cPLA 2 protein can be further activated by 
calcium ionophore A23187. 
3.5. The effect of TNF-oc on cPLA 2 mRNA levels 
cPLaa~ 
0 .~ 
t-. 
+ 4. + + l - - tO  
GAPDH-- 
Fig. 6. Effects of protein kinase inhibitors on cPLA 2 mRNA expression. 
Confluent BEAS 2B cells were treated with TNF-ct for 4 h with or 
without inhibitors. Inhibitors were added to the culture 10 min before the 
addition of TNF-c( (20 ng/ml).  The effects of various protein kinase 
inhibitors were displayed from the right as following: control cells; cells 
treated with TNF-cx; and cells treated with TNF-ot in the presence of 
staurosporine (2×10 -7 M), calphostin C (10 -7 M), genistein (0.1 
mg/ml),  and W-7 (30 /xM). Total RNA was purified and assayed by 
RPA as described in Section 2. The results are illustrated by autoradiog- 
raphy. The data represent one of four experiments with similar results. 
As TNF-oc increased cPLA 2 protein synthesis in the 
BEAS 2B cells, we then assessed the cPLA 2 mRNA level 
following TNF-cc treatment. The cPLA 2 mRNA levels in 
control and TNF-ot-treated cells were analyzed by ribo- 
nuclease protection assay (RPA) and RT-PCR. Fig. 5 
shows the time course effect of TNF-ot (20 ng/ml)  on 
cPLA 2 mRNA levels measured by RPA. TNF-cc induced 
a significant increase of cPLA 2 mRNA accumulation fol- 
lowing 4-24 h treatment. These results demonstrated that 
TNF-oc increased cPLA 2 mRNA expression and thus 
increased cPLA 2 protein synthesis in the BEAS 2B cells. 
In addition, we also studied the effect of different protein 
kinase inhibitors on cPLA z mRNA expression. The TNF- 
ot-induced increase in cPLA 2 mRNA was inhibited by 
TNF(x 
cPL.  
GAPDH 
Fig. 5. A representative RPA experiment assessing the effect of TNF-ot 
on cPLA 2 mRNA expression. The cells were treated with TNF-a (20 
ng/ml)  for 4-24 h and total RNA was purified. 10-20 /xg of the total 
RNA were hybridized to cPLA 2- and GAPDH-specific radiolabeled RNA 
probes and assayed by RPA as described in Section 2. The protected 
RNA fragments of cPLA2 (306 bases) and GAPDH (316 bases) were 
visualized by autoradiography. The data represent one of three separate 
experiments with similar results. 
staurosporine, calphostin C and W-7, but not by genistein 
(Fig. 6). Therefore, the above protein kinase inhibitors 
exhibited a very similar effect on the TNF-ct-induced 
expression of cPLA 2 mRNA as well as cPLA 2 protein. 
These results demonstrate hat the TNF- ot -induced cPLA 2 
gene expression requires PKC as well  as 
calcium/calmodulin-dependent protein kinases. 
To assay whether TNF-ot increases cPLA 2 mRNA and 
protein expression by stimulating ene transcription, con- 
fluent cultures of BEAS 2B cells were stimulated with 
TNF-ot (20 /xg/ml) for 30 min-4 h and the isolated 
nuclei were analyzed by a nuclear run-on assay as de- 
scribed in Section 2. TNF-oc stimulated the initiation of 
cPLA z gene transcription starting at 30 min after exposure 
and returning toward control level by 4 h. These prelimi- 
nary results suggest that TNF- cx induces the cPLA 2 gene 
expression at least in part by stimulating ene transcrip- 
tion. 
3.6. The effect of TNF-oc on the expression of non-pan- 
creatic group H PLA 2 
As the expression of non-pancreatic group II PLA 2 is 
induced by TNF-ot in renal mesangial cells and hepatoma 
cells [39,40], it was important to investigate whether this 
type of PLA 2 also contributes to the TNF- cx induced AA 
metabolism in the airway epithelial cells. RT-PCR, the 
most sensitive method for the detection of gene expression, 
was used to detect he expression of non-pancreatic group 
II PLA 2 in the BEAS 2B cells. Similar to the results 
obtained by RPA (Figs. 5 and 6), the RT-PCR analysis 
shows that the cPLA 2 mRNA is detectable under control 
conditions and is up-regulated by TNF-ot treatment (Fig. 
7A). While the group II PLA 2 mRNA was detected in the 
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Fig. 7. RT-PCR experiments a sessing the cPLA 2 and group II PLA 2 
mRNA expression. The amplified products of /3-actin (510 bp) and the 
corresponding products of cPLA 2 (306 bp) and group II PLA 2 (823 bp) 
were shown. (A) shows the cPLA 2 mRNA expression i control and 
TNF-cc treated BEAS 2B cells. The cells were treated with TNF-c~ (20 
ng/ml) for 8 h. (B) shows the group II PLA 2 expression i  BEAS 2B 
cells (control and TNF- cc treatment) as well as in human lung tissue. The 
results were displayed from the right as following: control cells; cells 
treated with TNF-~ (20 ng/ml) for 4 h, 12 h, and 24 h; and 50 ng of 
human lung poly(A)+ RNA. The result shown is a representative of 3 
separate experiments. 
poly(A) + RNA purified from human lung tissue, it was 
not detectable in both control and TNF-ot treated BEAS 
2B cells (Fig. 7B). These results demonstrate that the 
BEAS 2B cells do not contain group II PLA 2 and TNF- oc 
has no effect on its expression in these cells. 
4. Discussion 
In the respiratory system, the airway epithelium plays 
an active role in initiating and modulating airway inflam- 
mation [41]. Freshly isolated or cultured airway epithelial 
cells generate and release AA metabolites and PAF in 
response to various stimuli and release of these mediators 
may be important in the pathogenesis of disorders charac- 
terized by airway inflammation, such as asthma. The cur- 
rent study demonstrates that TNF-oc induces the synthesis 
and prolonged activation of cPLA 2 in human bronchial 
epithelial cells. TNF-ot induced a significantly increased 
release of prelabeled [3H]arachidonic acid (AA) following 
4-24 h incubation. Calcium ionophore A23187 (10 -5 M) 
further increased the [3H]AA release from the TNF-ot-  
treated cells. In vitro activity assay revealed that TNF-ot 
increased the DTT-resistant PLA 2 activity which was 
blocked by the cPLA 2 inhibitor AACOCF 3. Immunoblot 
of the crude cytosol fractions showed that treatment with 
TNF-oc increased the amount of cPLA 2 protein (110 
kDa). Ribonuclease protection assay and RT-PCR showed 
that TNF-oc (20 ng/ml)  increased the cPLA 2 mRNA 
level following 4-24 h treatment. The TNF-cz induced 
cPLA 2 mRNA and protein expression was inhibited by the 
broad inhibitor of protein kinases staurosporine, the protein 
kinase C (PKC) inhibitor calphostin C, and by the cal- 
cium/calmodulin-dependent pro ein kinase inhibitor W-7. 
Nuclear run-on experiments demonstrate that TNF-c~ 
induced cPLA 2 gene expression at least in part by stimu- 
lating gene transcription. RT-PCR amplification of the 
non-pancreatic group II PLA 2 mRNA showed that the 
group II PLA 2 is expressed in human lung but not in the 
BEAS 2B cells. TNF-ot failed to induce the expression of 
group II PLA 2 in the BEAS 2B cells. These results 
demonstrate that the cPLA 2 gene expression is up-regu- 
lated by TNF-ot in airway epithelial cells. 
Although TNF-ot induced [3H]AA release from the 
BEAS 2B cells following 4, 12 and 24 h treatment, the 
effect peaked at 12 h. The [3H]AA release at 24 h in both 
control and TNF-oc -treated cells is lower than that at 4 h. 
This pattern is different from the TNF-ct -induced expres- 
sion of cPLA 2 mRNA and protein as well as the TNF-ot - 
induced increase in the in vitro assayed PLA 2 activity, 
which showed greater effect following TNF-oc treatment 
for 12 and 24 h. As the measured level of [3H]AA in the 
supernatants reflects the balance between the release of 
AA from and its reincorporation i to membrane phospho- 
lipids, the AA reincorporation i to phospholipids mediated 
by an acyl-CoA lysophosphatide acyltransferase may be 
responsible for the lower level of [3H]AA measured at a 
longer incubation period (24 h). In fact, it has been 
reported that in addition to its AA-selective phospholipase 
A 2 activity, the cPLA 2 also exhibits lysophosphatide acyl- 
transferase activity [12]. Thus, the measurement of re- 
leased AA may be affected by the synthesis and activation 
of different PLA2s as well as factors other than PLA 2 
activation such as AA reincorporation. In this study, we 
demonstrated that the group II PLA 2 is not expressed in 
the BEAS 2B cells. Therefore, the TNF-ot-induced AA 
release is most likely due to the increased synthesis and 
activation of cPLA 2. The possible contribution of other 
forms of PLA 2 such as the CaZ+-independent PLA2s in 
the airway epithelial cells remains to be elucidated. 
Lung tissue contains a high level of PLA 2 activity. 
Immunoblot and Northern blot analysis have demonstrated 
the existence of the low molecular weight PLA2s in lung 
tissues from various species including rat, guinea pig and 
human. The existence of high molecular weight cPLA 2 in 
rat lung tissue has been demonstrated by immunoblot [46]. 
However, little is known about the characterization and 
regulation of different forms of PLA 2 s in specific lung cell 
populations. The widespread expression of cPLA 2 in vari- 
ous cell types, its exclusive intracellular location, its acti- 
vation by physiologically relevant concentrations of Ca 2+, 
its activity regulation by phoshorylation, and the enzyme 
synthesis regulation by cytokines make this enzyme an 
obvious candidate for the physiological regulation of 
eicosanoid synthesis in various cells including the airway 
epithelial cells. In this study, we found that the expression 
of cPLA 2 is readily detected by immunoblot, RPA and 
RT-PCR in the BEAS 2B cells but the group II PLA 2 
expression was not detectable by the most sensitive method, 
RT-PCR. As there exists a single gene for group II PLA 2 
in humans [13,14], this result indicates that the group II 
PLA 2 is not expressed in BEAS 2B cells. This finding is 
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in agreement with the results from the in vitro PLA 2 
activity assay. The PLA 2 activity was assayed using phos- 
phatidylcholine as substrate in the presence of the reducing 
agent DTT. This assay condition is optimal for the cPLA 2 
with very little contribution from the low molecular weight 
PLAzs [24-27]. Furthermore, the measured activity was 
significantly blocked by the novel cPLA~ inhibitor 
AACOCF 3 [47,48]. As AACOCF 3 is a specific inhibitor 
for cPLA 2 with no apparent effect on the low molecular 
weight PLAes, the significantly reduced activity in the 
presence of AACOCF 3 indicates that the measured activity 
is unlikely to be from the low molecular sPLA2s. The 
observation that TNF-~ induced PLA 2 activity is com- 
pletely blocked by AACOCF 3 also indicates that the low 
molecular sPLA2s are unlikely to be induced by TNF-~ 
treatment in these cells. Therefore, our results demonstrate 
that the group II PLA 2 does not exist in the BEAS 2B 
cells and it cannot be induced by TNF-a  treatment in 
these cells. Thus this type of PLA 2 is apparently not 
responsible for AA release in the BEAS 2B cell. The 
TNF-cx induced cPLA 2 expression contributes to the 
TNF-cx induced AA release and eicosanoid formation in 
these cells. 
The present study indicates that TNF- cc induced cPLA 2 
gene expression may require a protein kinase cascade. The 
TNF-cx-induced cPLA 2 mRNA and protein expression 
was inhibited by staurosporine, a broad inhibitor of protein 
kinases, suggesting that protein kinases are required for the 
TNF-c~-induced cPLA 2 gene expression. The protein ki- 
nase C (PKC) inhibitor, calphostin C, blocked the TNF- 
-initiated cPLA 2 gene induction, indicating that PKC is 
involved in TNF-cx-induced cPLA 2 gene expression. 
Calphostin C interacts with the regulatory domain of PKC 
and specifically inhibits PKC by competing at the binding 
site of diacylglycerol and phorbol esters [49,50]. It exhibits 
no effect on other protein kinases at nanomolar concentra- 
tions. Thus, the block of TNF-cx -induced cPLA2 protein 
and mRNA increase by calphostin C strongly suggests that 
PKC is involved in TNF-cx-induced cPLA 2 gene expres- 
sion. W-7, a calmodulin antagonist that binds to calmod- 
ulin and inhibits calcium/caimodulin-dependent pro ein 
kinases [51,52], also inhibited the cPLA 2 expression in 
response to TNF-~,  suggesting the requirement of the 
calcium/calmodulin-dependent protein kinases. Therefore, 
our results uggest that the TNF- c~ -induced cPLA 2 mRNA 
and protein expression reqaires the activation of a protein 
kinase cascade, including PKC and calcium/calmodulin- 
dependent protein kinases. 
As TNF-~ induces the synthesis of cPLA 2 protein, the 
exposure of TNF-cx-treated cells to a second PLA 2- 
activating stimulus such as the calcium ionophore A23187 
might result in a further increase in [3H]AA release. We 
found that the cells stimulated with TNF-ot showed a 
marked increase in [3H]AA release in response to subse- 
quent ionophore A23187 stimulation. Similar results have 
been found in the IFN-y-treated cells [35]. These findings 
indicate that the induced cPLA 2 protein cannot only be 
manifest as PLA 2 enzyme activity, it also may provide an 
enzyme source to be further activated by other stimuli. 
This may be a mechanism for the formation of airway 
inflammation and bronchial hyperresponsiveness, which 
exist in asthma, cystic fibrosis, chronic bronchitis, and 
atopic rhinitis [53]. As both TNF-cx and IFN-y are multi- 
fuctional cytokines, which have been implicated in airway 
inflammation, the airway epithelium may become hyperre- 
active by this mechanism to a variety of inflammatory 
mediators or external stimuli. 
Evidence suggests that the group II PLA 2 present in 
inflammatory exudates may enhance T-lymphocyte activa- 
tion and participate in the lysis of bacteria as well as in 
local and systemic inflammatory responses [14]. The exis- 
tence of group II PLA 2 in human lung supports the 
possibility that this type of PLA 2 may also participate in 
airway inflammation. The mechanisms of the proinflam- 
matory role of the group II PLA 2 are not clear but may 
involve direct cytotoxicity due to hydrolysis of cell mem- 
brane phospholipids and the generation of proinflamma- 
tory lipid mediators from cell membranes. The results 
presented in this study indicate that the airway epithelial 
cell is unlikely to be a major source of group II PLA 2. 
Other lung cells, especially the migratory inflammatory 
cells, may contain this type of PLA 2. As airway epithe- 
lium may play an important role in airway inflammation 
[41], it is likely that the airway epithelial cell may be one 
of the important argets for the extracellularly released 
group II PLA 2. To further understand the role of group II 
PLA 2 in airway inflammation, future studies are needed to 
identify the major cellular source of group II PLA 2 in 
human lung tissues and to demonstrate that this type of 
PLA 2 is also not expressed in non-transformed airway 
epithelial cells. 
Because cPLA 2 plays a central role in providing AA 
and lysophospholipid for subsequent metabolism to prosta- 
glandins, leukotrienes, HETEs and PAF, potent lipid medi- 
ators of inflammation, the synthesis and activation of 
cPLA 2 by TNF-cc may play an important role in mediat- 
ing some TNF-cx -induced biological functions. 
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